Page Loading...
Layout Table~~~~1429~1429~~
The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023~
Published By VisionGain, June 2008

Visiongain have the pleasure of announcing the latest edition of their industry leading report - The World OTC Pharmaceutical Market, 2008-2023. This edition updates the world OTC market at present and predicts its sales revenues and trends from 2008-2023, including drivers and restraints on the market. Sources used include industrial databases, commercial and financial news, published reports and policy documents, interviews and questionnaires. Visiongain applied financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market-based report with detailed analysis and informed opinion. The report examines the worldwide OTC market, breaking down present and forecasted sales revenues into leading therapeutic categories and national markets. Visiongain also provides forecasts for leading OTC brands.~Published by VisionGain, June 2008

Visiongain have the pleasure of announcing the latest edition of their industry leading report - The World OTC Pharmaceutical Market, 2008-2023. This edition updates the world OTC market at present and predicts its sales revenues and trends from 2008-2023, including drivers and restraints on the market. Sources used include industrial databases, commercial and financial news, published reports and policy documents, interviews and questionnaires. Visiongain applied financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market-based report with detailed analysis and informed opinion. The report examines the worldwide OTC market, breaking down present and forecasted sales revenues into leading therapeutic categories and national markets. Visiongain also provides forecasts for leading OTC brands.

In particular, this report concentrates on the following essential aspects of the global OTC industry:Why you should buy this report:Visiongain forecasts that OTC pharmaceutical sales will almost double from 2007 levels by 2023. In the period 2008-2023, the worldwide OTC market will undergo a period of dynamic change. Increasingly aging populations and rising incidence of lifestyle diseases, as well as the need to reduce healthcare costs, will open up new therapeutic areas for OTC switching. Likewise, sales of existing OTC products will rise. At the same time, changes in retail patterns and new ways of advertising will open up access to OTC drugs to a public better educated and more interested in self-medication than at any previous time. Taking advantage of such opportunities will take considerable skill in a crowded and competitive marketplace. Consequently, the commercial prospects are very good for companies well placed to serve those growing needs. In these difficult times for the global pharmaceutical industry, OTC sales will become increasingly important, visiongain concludes.

Further unique benefits to you when you order this report:Sample Pages~The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023 (Single User License)|1186|The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023 (Departmental License)|1187|The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023 (Company Wide License)|1188|~1429~3354~~
The Pharmaceutical Wholesale and Distribution Industry Outlook & Analysis 2008~
Published by VisionGain, June 2008

The major problem facing the Wholesale & Distribution industry is its low profit margin which is in the region of only 1-2%. However, this market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition. As generics are priced lower than their branded counterparts, the actual dollar profit on them taken by W&D companies, for their movement, is reduced. In the light of this, other key factors such as new pricing and distribution models are also discussed in more detail.~Published by VisionGain, June 2008

The major problem facing the Wholesale & Distribution industry is its low profit margin which is in the region of only 1-2%. However, this market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition. As generics are priced lower than their branded counterparts, the actual dollar profit on them taken by W&D companies, for their movement, is reduced. In the light of this, other key factors such as new pricing and distribution models are also discussed in more detail. Other important issues that are affecting the industry and discussed in detail include:
  1. Drug Counterfeiting
  2. Direct-to-Pharmacy Distribution
  3. Parallel Trade
  4. Canada and US Drug Reimportation
  5. Internet drugs: Mail Order and On-line Pharmacies.
The objectives of this report are to understand the W&D industry, why it occurs, who it affects, different natures of wholesale-distribution and what kinds of strategies are involved. Wholesale-Distribution has both pros and cons for different healthcare stakeholders. Wholesale-Distribution is a complex area, where there are many “grey” areas.

In particular, The Pharmaceutical Wholesale and Distribution Sector concentrates on the following essential aspects of the industry:This report examines the industry critically through a comprehensive review of available information, including that from commercial databases and other highly relevant sources, including SWOT analysis. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

Why you should buy this report: Sample Pages~The Pharmaceutical Wholesale and Distribution Industry Outlook & Analysis 2008 (Departmental License)|1192|The Pharmaceutical Wholesale and Distribution Industry Outlook & Analysis 2008 (Company Wide License)|1193|~1429~3359~~
The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023~
Published by VisionGain, May 2008

The pharmaceutical industry is one of the fastest growing sectors in Indian economy. Visiongain predicts that market for pharmaceuticals in India has strong potential for increased growth from 2008 right through to 2023. The industry’s leading Indian Pharma report contains unique market-based research, including detailed interviews with key opinion leaders based in India and abroad. Importantly, the report forecasts the overall Indian pharmaceutical market from 2008 to 2023, as well as that of many important market segments. Other key metrics are also included throughout the report. This is your opportunity to gain critical insight into the potential and inner workings of one of the world’s most important healthcare markets from the present onwards.~Published by VisionGain, May 2008

The pharmaceutical industry is one of the fastest growing sectors in Indian economy. Visiongain predicts that market for pharmaceuticals in India has strong potential for increased growth from 2008 right through to 2023. The industry’s leading Indian Pharma report contains unique market-based research, including detailed interviews with key opinion leaders based in India and abroad. Importantly, the report forecasts the overall Indian pharmaceutical market from 2008 to 2023, as well as that of many important market segments. Other key metrics are also included throughout the report. This is your opportunity to gain critical insight into the potential and inner workings of one of the world’s most important healthcare markets from the present onwards.

This new visiongain report describes India’s domestic as well as export market for pharmaceuticals. India has had a strong domestic pharmaceutical industry and a rapidly expanding market with a population of over a billion and a rapidly expanding economy. Prevalence values of many diseases are likely to increase with expansion of population, urbanisation and with higher identification rates in the coming decade. India's pharmaceutical market is increasingly important in global pharma, with both domestic and foreign companies benefiting. Healthcare provision – both public and private – is improving, leading to fast-expanding markets for healthcare products, especially modern pharmaceuticals, visiongain concludes.

Outsourcing for Contract Research and Manufacturing Services from India

The report also analyses India’s role in pharma outsourcing services. India is emerging as a competitive outsourcing hub and is playing a major role in the global pharmaceutical industry in manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates for drug makers. Global pharmaceutical companies are establishing long-term relationships with Indian manufacturing companies and contract research providers in India.

Generic drugs produced in India are increasingly being accepted worldwide, with leading companies such as Ranbaxy, Cipla and Dr. Reddy’s paving the way for others. Indian companies have increasingly taken on outsourced manufacturing for foreign clients, in addition to marketing pharmaceuticals themselves. There are also new drug development programmes by Indian companies, with eventual international market launches. Outsourcing to India has proven to be effective in saving costs and valuable developmental time. The Indian pharmaceutical industry has taken an important role in global pharma, not only as a manufacturer of generic drugs and APIs but also of new formulations.

Increasing costs for research and development and low productivity have compelled major pharmaceutical companies worldwide to outsource part of their research and manufacturing activities to lower-cost, developing nations such as India and China. India's emphasis on research and development and new drug discovery is growing. Furthermore, India is emerging as the preferred destination for outsourcing clinical trials, with both high quality and lower costs achieved there. Why You Should Buy This Report

In this report you will receive the following essential information for understanding the Indian pharma market and industry:This Report is essential reading for the Following Professionals, Amongst Others:Unique Benefits When You Order This Report:Great Potential for the Indian Pharma Sector and Market from Present Onwards, Visiongain Concludes
Currently, India's largest selling medicines are anti-infective agents, but the fast growing areas are the lifestyle-related diseases, the foreign multinational companies will benefit from selling innovative treatments for these conditions.

With increasing prevalence of diseases of aging and lifestyle-related diseases associated with greater affluence, India's pharmaceutical market will continue to increase steadily in sales value from 2008 onwards. Furthermore, with rapid increase in drug resistance for anti-infective agents like anti-TB, anti-malarial and other antibiotics, visiongain further emphasises that there will be a particularly strong market for most types of pharmaceutical agents – both new and established - from 2008 to 2023.

Sample Pages~The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023 (Single User License)|1194|The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023 (Departmental License)|1195|The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023 (Company Wide License)|1196|~1429~3361~~
Chinese Pharmaceutical Outlook 2008-2023~
Published by VisionGain, April 2008

This brand new report examines the prospects for the growth of pharmaceutical revenues in China. Visiongain predicts that total pharmaceutical revenues in China will increase from approximately $12bn in 2007 to over $30bn in 2013. This is a considerable increase, one that will represent a near tripling of total sales over six years. Strong growth will continue well beyond that period, as this report shows and explains.~Published by VisionGain, April 2008

This brand new report examines the prospects for the growth of pharmaceutical revenues in China. Visiongain predicts that total pharmaceutical revenues in China will increase from approximately $12bn in 2007 to over $30bn in 2013. This is a considerable increase, one that will represent a near tripling of total sales over six years. Strong growth will continue well beyond that period, as this report shows and explains.

Over 220 pages full of analysis, graphs, tables and charts – available to you today.

If you are interested in pharmaceutical business in China, you cannot afford to be without this report by visiongain’s leading authority on developing pharmaceutical markets. Visiongain’s Chinese Pharmaceutical Outlook 2008-2023 examines the exciting Chinese pharmaceutical market and industrial sector critically through comprehensive research and analysis. Visiongain applied techniques such as financial forecasting, surveying of key opinion leaders, SWOT analyses and discussion of qualitative factors. Societal, political, economic and commercial issues are covered. The result is a comprehensive market-based report with detailed analysis and informed opinion. This original 220+ page study contains 57 tables and 47 figures. We invite you to examine the table of contents included here.

In particular, visiongain’s Chinese Pharmaceutical Outlook 2008-2023 concentrates on the following themes:Why you should buy this report: The dominant pharmaceutical markets of North America, Western Europe and Japan currently account for over 80% of revenues for prescription drugs worldwide. However, there is great concern about the relatively low growth of those established markets in recent years. Consequently, international pharmaceutical companies are striving to raise their profiles in the developing markets of Asia, Latin America and Eastern/Central Europe. Principal amongst those developing markets is the emergent demographic and economic colossus of China.

Growth of the pharmaceutical markets in developing nations will clearly surpass that of the established markets throughout the foreseeable future. That situation will provide one of the greatest opportunities ever available to the international pharmaceutical industry. Those strongly growing national economies drive the reform and broadening of healthcare systems, with increasing sales in all healthcare sectors. Improvements in both the quality and reach of these healthcare provisions will drive the sales of branded and generic drugs in particular. This report will help you to understand those developments and opportunities.

Other benefits to you when you order this report:Sample Pages~Chinese Pharmaceutical Outlook 2008-2023 (Single User License)|1204|Chinese Pharmaceutical Outlook 2008-2023 (Departmental License)|1205|Chinese Pharmaceutical Outlook 2008-2023 (Company Wide License)|1206|~1429~3370~~
Lipitor Market analysis and forecasts Report, 2007-2012, 2017 & 2023~
Published by VisionGain, April 2008

In 2006, Pfizer’s Lipitor (atorvastatin) generated global revenues of $13.6bn, making it the best selling drug in pharmaceutical history. The blockbuster medicine has single-handedly driven the overall revenue margins of the cardiovascular segment, as this area continues to dominate the pharmaceutical market. Despite the maturing status of Lipitor, the drug has repeatedly maintained steady growth over the past 5 years, crowding out the yearly revenues of other lipid-regulating blockbuster drugs: Merck& Co’s Zocor and Zetia, Astrazeneca’s Crestor, Abbott’s Tricor and Bristol Myers Squibb’s Pravacol.~Published by VisionGain, April 2008

In 2006, Pfizer’s Lipitor (atorvastatin) generated global revenues of $13.6bn, making it the best selling drug in pharmaceutical history. The blockbuster medicine has single-handedly driven the overall revenue margins of the cardiovascular segment, as this area continues to dominate the pharmaceutical market. Despite the maturing status of Lipitor, the drug has repeatedly maintained steady growth over the past 5 years, crowding out the yearly revenues of other lipid-regulating blockbuster drugs: Merck& Co’s Zocor and Zetia, Astrazeneca’s Crestor, Abbott’s Tricor and Bristol Myers Squibb’s Pravacol.

However, as Lipitor’s blockbuster revenue is seriously threatened by imminent patent expiration in some of the drug’s largest markets such as the US, Japan and the UK, there is significant unrest between Pfizer’s key stakeholders about the future of the drug. Principally, amongst the heightened Lipitor topics are the imminent exposure of the $1 billion annual drug sales or more, as well as the fast expanding generic market in which India’s Ranbaxy is a dominant force.

What questions does the report answer? As Pfizer’s Lipitor struggles to fend off the immediate entry of Ranbaxy’s generic Lipitor, in key markets, the legal challenges surrounding the number one drug have set a new benchmark for pharmaceutical companies protecting branded products. Industry observers including Visiongain predicts that Pfizer’s crises are far from over, as the high revenue streams of Lipitor will experience significant challenges before the commencement of the next decade.

Moreover, Pfizer’s lack of success to replace Lipitor with Torcetrapib has escalated the company’s near-term battles besides the ever-tighter regulatory hurdles, reduced R&D efficiency and increased competition, creating formidable therapeutic challenges as healthcare payers influence pricing. Nevertheless, there are strong drivers of growth including unmet therapeutic needs, the rising incidence of multiple diseases, ageing populations, the rising living standards and fast-developing geographical markets. The future of Lipitor is therefore vitally important to Pfizer, especially in this uncertain period of economic changes and pressures.

This report includes detailed five-year forecasts over the period 2008-2013, and NOW features 10 and 15-year forecasts to help you understand the medium-term prospects for these markets.

Why You Must Buy This Report:

This unique in-depth management report examines the future prospects for Lipitor from 2008-2023. It delivers direct to you future sales forecasts for leading Lipitor in all seven major markets (7MM). This detailed report highlights the most compelling must know issues- Lipitor’s patent contention by Pfizer in both 7MM and other markets in order to block Ranbaxy’s immediate penetration of generic Lipitor. In light of healthcare drug bills increasing exponentially, generic Lipitor will be welcomed by managed care organisations (MCO) and further widen the generic revenue margins, visiongain concludes. This report also tackles Lipitor’s significant developments, potential opportunities on the market and important contemporary matters, especially commercial drivers and restraints.

Unique benefits to you when you order this report:Sample Pages~Lipitor Market analysis and forecasts Report, 2007-2012, 2017 & 2023 (Single User License)|1210|Lipitor Market analysis and forecasts Report, 2007-2012, 2017 & 2023 (Departmental License)|1211|Lipitor Market analysis and forecasts Report, 2007-2012, 2017 & 2023 (Company Wide License)|1212|~1429~3373~~
Blood Disorders Market Analysis & Forecasts Report to 2013~
Published by VisionGain, April 2008

In 2007, blood diseases cost the US’s economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. From oxygen delivery to immunological defence to clotting, blood has vital physiological functions, and clear, expensive treatments.~Published by VisionGain, April 2008

In 2007, blood diseases cost the US’s economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. From oxygen delivery to immunological defence to clotting, blood has vital physiological functions, and clear, expensive treatments. This brand new blood diseases treatments report breaks down therapies into four main groups:In 2006 visiongain valued this market at $37406m, But do you know how the blood diseases treatments market will fare 5, 10 and 15 years from now? Will it increase in sales and bring in significant profits or will it be rocked by widespread patent expiration and ensuing generic competition? This report provides these answers, with detailed quantitative and qualitative analysis. This is information every player in the blood diseases treatments market should not be without.

Visiongain’s new Blood Disorders 2008 report covers:This study was achieved through research of relevant news, company reports, expert opinion, academic literature and gold-standard IMS databases. Financial forecasting based upon in-depth research was performed, with accompanying SWOT analyses. The result is a comprehensive market-based study with extensive analysis and informed opinion.

Why You Should Buy This Report

This 115+ page report features over 25 tables, 50 graphs, market forecasts, current news, detailed insight, the latest developments, all with up-to-date analysis and informed opinion. This visiongain report is a vital aid to your gaining an understanding of this important market sector, giving your company 'the edge' on its competitors.

Importantly report gives answers to relevant questions such as:Other benefits to you when you order this report:Sample Pages~Blood Disorders Market Analysis & Forecasts Report to 2013 (Single User License)|1216|Blood Disorders Market Analysis & Forecasts Report to 2013 (Departmental License)|1217|Blood Disorders Market Analysis & Forecasts Report to 2013 (Company Wide License)|1218|~1429~3377~~
Sleep Disorders Market Analysis 2008-2018~
Published by VisionGain, March 2008

The market penetration for insomnia drugs has not reached saturation point. Opportunities remain. But with the introduction of several new products the market is set to see changes, but expansion. This expansion is based on increased general awareness physicians better comprehension of the significance of this disease and the positive role that a sleep medication prescription plays.~Published by VisionGain, March 2008

More than 80 sleep disorders have been identified. They affect over 200 million people worldwide. The report focuses on the market for following sleep disorders:The market penetration for insomnia drugs has not reached saturation point. Opportunities remain. But with the introduction of several new products the market is set to see changes, but expansion. This expansion is based on increased general awareness physicians better comprehension of the significance of this disease and the positive role that a sleep medication prescription plays.

At present time there are several prescription sleeping medications available to treat insomnia. The market-focus has been driven by the production of sleep medications with less side-effects and danger of overdose. Prescription benzodiazepines and newer non-benzodiazepine hypnotics developed in the 1990s, such as Imovane, Ambien and Sonata will continue to be the most prescribed. Benzodiazepines are widely used to treat an underlying neurological disorder which is often the underlying cause of insomnia, e.g. anxiety and depression.

Visiongain predicts that market share by volume for insomnia in the US will change significantly from 2008 to 2018. Ambien IR lost its patent protection in April 2007, which opened to generic competition for Zolpidem. Ambien will remain the market leader for the short term, but what will over take it? A generic version of Ambien is expected to achieve strong market share by volume as there is a great demand for zolpidem tartrate for insomnia.

The market share for insomnia treatment will gradually rise after 2012, which will be due to:Other drugs dealt with in this report include:Key findings that will broaden the scope of the sleep disorders market:What questions does the report answer? Why should you buy this report?Unique benefits to you when you order this reportSample Pages~Sleep Disorders Market Analysis 2008-2018 (Single User License)|1159|Sleep Disorders Market Analysis 2008-2018 (Departmental Lcense)|1160|Sleep Disorders Market Analysis 2008-2018 (Company Wide License)|1161|~1429~3346~~
The Antibacterial Drug Market Analysis 2008-2013~
Published by VisionGain, March 2008

This brand new market analysis by visiongain examines the prospects for antibacterial drugs from 2008-2013, including sales forecasts for leading pharmaceutical products. The antibacterial market is large in terms of disease area as well as the different drug classes used to treat these infections. However, this market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition. In the light of this, including other factors, visiongain predicts this market to decline in revenues – but which products will suffer most? How can you fight this generic competition? The antibacterial drug market generated revenues of $30274m in 2006 – but what will it be in 2013? Only this brand new report will tell you.~Published by VisionGain, March 2008

This brand new market analysis by visiongain examines the prospects for antibacterial drugs from 2008-2013, including sales forecasts for leading pharmaceutical products. The antibacterial market is large in terms of disease area as well as the different drug classes used to treat these infections. However, this market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition. In the light of this, including other factors, visiongain predicts this market to decline in revenues – but which products will suffer most? How can you fight this generic competition? The antibacterial drug market generated revenues of $30274m in 2006 – but what will it be in 2013? Only this brand new report will tell you.

The antibacterial market only contained one blockbuster drug in 2006, this being Johnson & Johnson’s Levaquin. Visiongain predicts that there will be room for one more blockbuster drug as Levaquin will lose patent protection. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints.

This report will specifically analyse the world markets for the following classes of antibacterials: The group 'miscellaneous' is an assorted group of antibacterials which includes the minor classes: the tetracyclines, aminoglycosides, glycopeptides and sulphonamides plus individual antibacterials such as Zyvox and Vancocin.

The Antibacterial Drug Market Analysis 2008 examines the market critically through a comprehensive review of available information. Sources include industrial databases, commercial news, published reports, economic research and consultation with experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

In particular, The Antibacterial Drug Market concentrates on the following essential aspects of the market:Why you should buy this report:
Respiratory Market Insight 2008~
Published by VisionGain, February 2008

This brand new report examines the forthcoming prospects for respiratory drugs over the next 5 year. With in-depth sales forecasts for leading pharmaceutical products, the report has been produced to inform you of future developments and strategies. The respiratory market generated revenues of $30503m in 2006, but what will it be in 2013,? Which year will see it reach its peak? This report tells you.~Published by VisionGain, February 2008

This brand new report examines the forthcoming prospects for respiratory drugs over the next 5 year. With in-depth sales forecasts for leading pharmaceutical products, the report has been produced to inform you of future developments and strategies. The respiratory market generated revenues of $30503m in 2006, but what will it be in 2013,? Which year will see it reach its peak? This report tells you.

The respiratory market contained ten blockbuster drugs in 2006, with the top three being; Advair/Seretide, Singulair and Zyrtec. Visiongain predicts that there will be room for more blockbusters as the current products lose patent protection. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints.

The prevalence of respiratory diseases such as asthma, in the leading pharmaceutical markets, has increased significantly over the past few decades. Although there is some evidence to suggest that the rate of increase is slowing, we believe that the prevalence will continue to increase and be a key driver of this market throughout the forecast period of the report.

Sources include primary interviews and analysis unavailable elsewhere, in-house industry databases, commercial news, published reports, economic research and consultation with experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

In particular, The Respiratory Market concentrates on the following essential aspects of the market:Why you should buy this report: Do you know what the market values of these major therapeutic areas of the respiratory market are?

The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC respiratory drugs by product type. The study also assess' the challenges faced by respiratory companies, and what exciting market opportunities exist in this up- and-coming therapeutic area.

Why You Must Buy This Report?

This report features over 40 figures & graphs, 15 tables and charts, news, insights, the latest developments and an in depth survey of the respiratory market with up-to-date analysis. This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company 'the edge' on your competitors. You can not afford to be without this latest report from visiongain

Sample Pages~Respiratory Market Insight 2008 (Single User License)|1165|Respiratory Market Insight 2008 (Departmental License)|1166|Respiratory Market Insight 2008 (Company Wide License)|1167|~1429~3352~~
Generic League - Market Analysis and Forecasts, 2007-2012, 2017 & 2022~
Published by VisionGain, February 2008

The generic industry is a fast evolving market; with significant lucrative opportunities. The generic market is structurally set to experience high growth potential. That wave is partly driven by cost-containment in several national healthcare sectors and partly by the need for governments to promote the use of generic products over high-priced originator products without compromising quality.~Published by VisionGain, February 2008

The generic industry is a fast evolving market; with significant lucrative opportunities. The generic market is structurally set to experience high growth potential. That wave is partly driven by cost-containment in several national healthcare sectors and partly by the need for governments to promote the use of generic products over high-priced originator products without compromising quality.

In 2006, the global generics market attained strong revenues of approximately $65bn, up by 12% in comparison with $58bn in 2005. However, during the same period, the Top Ten leading generic suppliers generated total revenues of $27.9bn, up by a growth rate of 34%. The Top Five Companies within that sector experienced significant revenues, with market growth largely driven by significant commercial activities, key Mergers and Acquisition (M&A) and launch of new product in the leading markets.

In light, of the significant number of proprietary branded pharmaceuticals approaching patent expiration in the near-term, visiongain predicts that the generic market is set to experience further market expansion during the forecast period. Visiongain also predicts that by 2023, the Top Ten leading generic suppliers will experience CAGR of 7%. That significant CAGR, will be driven by generic versions of leading blockbuster drugs presently estimated at $100bn, nearing patent expiration during 2008-2012.

Prominently, amongst the products with looming patent expirations are drugs such as:

In 2007, a total of 14 drugs came of patent in the US market. In 2008, a total of 14 drugs are expected to lose patent protection in the US market. In 2009, five drugs are predicted to becoming off-patent in the US market. On the 24 of March 2010, the world's highest selling drug, Pfizer's Liptor will come off-patent in the US. In the EU market, UCB's Keppra and four other medicines are expected to lose patent protection. In 2011, 10 major drugs in the US market will also become exposed to generic competition. An estimated 11 drugs will experience generic competition in the EU market during the same year. Significant among these drugs will be Lipitor and Zyprexa.

Moreover, the generic market is projected to further expand through the growing uptake of biogeneric/ biosimilar products. In 2006, biological drugs, the products of biotechnology generated total revenues of $40bn. The US market alone, accounted for a significant proportion of total worldwide sales. Presently, in the EU, the growing popularity of these products are gaining newer heights, with managed care organisations (MCOs), healthcare providers and payers amongst others increasingly requesting these medicines as a significant cost-saving strategy. However, by 2010, an estimated 24 biologic drugs will near patent expiration opening up the market for generic possibilities.

Visiongain’s market analysis forecast a-to- be lucrative era during the mid-term of our forecast where we believe, the Top Ten generic suppliers will see strong sales growth leveraged through licensing of new products.

With Top Ten company-by-company forecast focus on regions:

This report includes detailed five-year forecasts over the period 2007-2012, and NOW features 10 and 15-year forecasts to help you understand the medium-term prospects for these markets.

Why You Must Buy This Report:

This report features in-depth primary research, tables, graphs and charts, news, insights, the past and present developments in Market. This report will provide you with the complete understanding of operations of Top Ten companies that has driven their corporate growth in recent times. In addition, the report sheds significant emphasis on key strategies that will drive year-on-year sales growth of their leading products. Despite the lucrative opportunities presented to the leading companies through patent expirations, the visiongain reports analyses the key battles that the leading Top Ten generic companies will face during the same period.

This visiongain report is the single tool to equip you with the latest trends in all regional markets and why all (stakeholders) are opting for cheaper generic medicine, that are equally potent as their originator versions. Visiongain recommends this astute report to the major players in the field as it will arm you with the major legal challenges that leading companies face to date. The report, will also inform you on how the Top Ten generic companies are positioning themselves in facing the rising inherent cost of R&D expenditure especially on difficult-to-manufacture biogeneric/ biosimilars. In addition, the reports present a 360 degrees overview of requirements set by major regulatory authorities for larger evidence of clinical data before any authorisation.

When you buy this report, you will also get an understanding, through our overview; of how present changes in Governmental Pharmaceutical Policies with respect to cost-cutting coupled with major hurdles by that the Top Ten generic suppliers will have to overcome in the growing presence of price erosion /sensitivity in key and emerging markets. The Top Ten Generic League Market Analysis & Forecasts 2007-2023 report is a must buy, because it presents in-depth and unbiased financial analysis for the near-term, medium-term and the long-term, market dynamics.

When you buy the Visiongain 2008 Top Ten Generic League report, you will be buying current and vital information on the vast array of commercial opportunities marked for potential success in the long-term treatment of the generic market.

Unique benefits to you when you order this report:

What questions does the report answer?

If you work for any of the above companies then you really need to get to grips with why the leading generic companies are the leading companies. Don’t get left behind. Act today and order your copy of this innovative report.~Generic League - Market Analysis and Forecasts, 2007-2012, 2017 & 2022 (Single License)|1150|Generic League - Market Analysis and Forecasts, 2007-2012, 2017 & 2022 (Departmental License)|1151|Generic League - Market Analysis and Forecasts, 2007-2012, 2017 & 2022 (Company Wide License)|1152|~1429~3340~~
The Antipsychotics Market Insight & Analysis 2008~
Published by VisionGain, February 2008

The total antipsychotics market revenue in 2006 was $18.1bn. Visiongain predicts that total revenues in the antipsychotics market will peak to $18.6bn by 2007. But what will it be in 2012? This report will tell you.~Published by VisionGain, February 2008

The total antipsychotics market revenue in 2006 was $18.1bn. Visiongain predicts that total revenues in the antipsychotics market will peak to $18.6bn by 2007. But what will it be in 2012? This report will tell you.

This in-depth market analysis examines prospects for antipsychotic drugs right through to 2012, including sales forecasts for leading products. The antipsychotics market will face decreasing growth throughout the forecast period, due to the patent expiry of leading blockbuster drugs. Safety concerns over the current antipsychotics along with high prices, will also contribute to decreased growth in this market.

The antipsychotics market currently contains four blockbuster drugs; Zyprexa, Risperdal, Seroquel and Abilify. Visiongain predicts that a fifth drug will also reach blockbuster status by 2008. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints.

According to the National Alliance for Research on Schizophrenia and Depression, approximately 22.1 per cent of American adults (approximately 64 million people) suffer from a diagnosable mental illness in any given year. Of these, it is estimated that over 2 million suffer from schizophrenia. Similarly, approximately 18.8 million people have a depressive disorder, with approximately 2.3 to 3 million suffering from bipolar disorder.

The Antipsychotic Drugs Market Insight and Analysis 2008 examines the market critically through a comprehensive review of available information. Sources include primary research unavailable elsewhere, in-house and industrial databases, commercial news, published reports, economic research and consultation with experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

In particular, The Antipsychotics Market concentrates on the following essential aspects of the market:

Why you should buy this report: The future of current and potential anti-psychotic blockbusters is vitally important to each company. Off label allocation has seen companies write off funds for possible legal actions. Zyprexa-maker Lilly set aside $1.2 billion to settle 31,000 claims and still faces 1,200 cases and a federal probe. Bristol-Myers Squibb, maker of Abilify, agreed to pay $515 million last year, in part to settle off-label marketing allegations; the firms also face thousands of additional claims. AstraZeneca has 8,000 suits pending for Seroquel.

This report concentrates on arguably the most exciting challenge facing the anti-psychotic industry and regulators: how to adapt medicine to patient sub-populations and emerging regulatory demands, improving safety and efficacy markedly. No pharmaceutical company can afford to ignore those issues.

Sample Pages~The Antipsychotics Market Insight & Analysis 2008 (Single License)|1153|The Antipsychotics Market Insight & Analysis 2008 (Departmental License)|1154|The Antipsychotics Market Insight & Analysis 2008 (Company Wid License)|1155|~1429~3342~~
Peripheral Neuropathy and Neuropathic Pain, 2008~
Published by BioPharm Reports, January 2008

This report estimates that Peripheral Neuropathy (PN) and Neuropathic Pain (NP) affect 170 to 270 million individuals globally. PN and NP are causally linked to a number of diseases, however diabetes, cancer and HIV alone are expected to increase the prevalence of PN and NP by more than 10% by 2012. PN and NP are areas of significant and critical unmet need. There are no cures for PN and NP is difficult to treat and often unresponsive to all available therapies. Today's armoury of drugs for the treatment of NP shows significant reliance on "second-indication" drugs, which were initially developed to treat other primary indications (e.g. anticonvulsants, antidepressants).~Published by BioPharm Reports, January 2008

This report estimates that Peripheral Neuropathy (PN) and Neuropathic Pain (NP) affect 170 to 270 million individuals globally. PN and NP are causally linked to a number of diseases, however diabetes, cancer and HIV alone are expected to increase the prevalence of PN and NP by more than 10% by 2012. PN and NP are areas of significant and critical unmet need. There are no cures for PN and NP is difficult to treat and often unresponsive to all available therapies. Today's armoury of drugs for the treatment of NP shows significant reliance on "second-indication" drugs, which were initially developed to treat other primary indications (e.g. anticonvulsants, antidepressants). This report gives a comprehensive update on all current drugs, together with the entire drug development pipeline, from pre-clinical through to Phase III, Registration and initial Launch. The pipeline includes 80 candidates being developed to treat PN and NP as a primary indication and 60 "second-indication" drugs. More than 300 patents published in the PN and NP field between 2002 and 2007 have also been assessed and presented, together with the identification of potential candidate molecules and drug targets which have not entered the development pipeline, but which may do so in the future. This report was written to provide a comprehensive update on therapeutic developments relating to PN and NP, both in tackling its most serious and debilitating symptoms, but also in targeting and potentially correcting the underlying disease mechanisms. Commercial evaluation and assessments including markets, market size, market sectors, sales and trends relating to PN and NP are also included in this report.

Drug Targets

Most current and developmental therapies for neuropathic conditions are directed at NP. Moreover, many of today's commonly used drugs in this area were developed for other indications, but subsequently were found to offer useful application in the treatment of NP. These include anticonvulsants, antidepressants and others. These "second indication" drugs represent around 10 pharmacological mechanisms including 5 hydroxytryptamine uptake inhibitors, cannabinoid CB1 agonists, carnitine acetyltransferase stimulants, GABA receptor agonists, NMDA antagonist, opioid mu receptor agonists, sodium channel antagonists, tumour necrosis factor alpha antagonists and others of unidentified pharmacological activity. In contrast, only a few molecules have been developed specifically for NP as a primary indication and these include an aldose reductase inhibitor, a membrane integrity agonist and an opioid kappa receptor agonist. However, the last ten years have seen important advances in the understanding of peripheral neuropathy and neuropathic pain at the biological and pathophysiological level and this is reflected in the numbers of new candidates in the drug development pipeline. Today, there are more than 40 drug types in development for the treatment of PN or NP as primary indications, more than 30 of which are directed at new drug targets. Whilst most of these are directed at NP, a number are targeting the underlying disease mechanisms, offering the hope that NP disease progression may be blocked or even reversed. The development and extension of new and existing molecules for the treatment of NP and PN as second indication drugs continues, and collectively these two groups (i.e. primary + secondary indication drugs) represent over 60 different drug types. Recent patent filings, 2002-2007, show a significant number of other therapeutic opportunities which have not entered the drug development pipeline, but which may do so in the future. This report identifies these candidates on the basis of their mechanism of action, drug target, developmental stage, by company and other relevant areas.

Background and Questions

PN and NP are causally linked to a number of conditions including diabetes, auto immunity, infection, cancer, drugs or toxins, the autonomic nervous system and hereditary diseases. It is estimated in this report that PN and NP currently affect 170 to 270 million individuals globally, figures that are set to increase by more than 10% by 2012. This report discusses the major peripheral neuropathies as well as neuropathic pain, together with prevalence, trends and treatments. Some of the questions considered in this report include:
  1. which therapies are available for the treatment of PN and NP, their capabilities and failings, unmet need
  2. What is happening in the developments pipeline, which candidates are nearest to market
  3. what are the prevalences of the major neuropathies and what are the future anticipated trends
  4. what strategies are being developed in the treatment of PN and NP, prospects of success and failure
  5. which companies are developing new therapies for PN and NP
  6. what are the current market sizes relating to PN and NP, including market sectors, sales and anticipated growth over the next 5 years

Report Contents~Peripheral Neuropathy and Neuropathic Pain, 2008 (PDF)|1111|~1429~3312~~
Live-Licensing & In-life testing: R&D Processes and Regulation for New Drugs, 2008-2020~
Published by VisionGain, January 2008

Visiongain predict that the current phase I to IV clinical testing process will eventually be selectively or wholly replaced by a system known as “in-life” testing or “live” licensing. Those proposals involve cumulative testing of the drug throughout its lifecycle. The industry would continually test drugs with smaller, more focused clinical trials. If a trial shows efficacy and safety, a live license would be given, allowing the company to market the drug in a limited manner. Already, the FDA and the EMEA have shown favourable interest in such developments - amongst other amendments to current practice.~Published by VisionGain, January 2008

Visiongain predict that the current phase I to IV clinical testing process will eventually be selectively or wholly replaced by a system known as “in-life” testing or “live” licensing. Those proposals involve cumulative testing of the drug throughout its lifecycle. The industry would continually test drugs with smaller, more focused clinical trials. If a trial shows efficacy and safety, a live license would be given, allowing the company to market the drug in a limited manner. Already, the FDA and the EMEA have shown favourable interest in such developments - amongst other amendments to current practice.

In particular, R&D Processes and Regulation for New Drugs, 2008-2020, concentrates on the following essential aspects of the market:Why you should buy this report: Further clinical testing during the marketing of the drug could allow the marketing restrictions to be gradually lifted, providing access to greater numbers of patients, including an expansion of indications. This proposed testing system has the advantage of allowing companies to gain revenues from the drug candidate earlier, while benefiting patients earlier as well. The tests combined with treatment could also cut developmental costs significantly, since large-scale clinical testing is very costly and time consuming. This is a win-win situation for you and your company – you must be fully informed of it now.

Visiongain believes that in life testing/live licensing will be fully operative next decade.

The future of current and potential blockbusters is therefore vitally important to all companies in the pharmaceutical sector, especially in this period of economic pressures and regulatory uncertainty. This report concentrates on arguably the most exciting challenge facing the industry and regulators: how to adapt medicine to patient sub-populations and emerging regulatory demands, improving safety and efficacy markedly. No pharmaceutical company can afford to ignore those issues.

Sample Pages~Live-Licensing & In-life testing%3A R&D Processes and Regulation for New Drugs, 2008-2020 (Single User License)|1162|Live-Licensing & In-life testing%3A R&D Processes and Regulation for New Drugs, 2008-2020 (Departmental License)|1163|Live-Licensing & In-life testing%3A R&D Processes and Regulation for New Drugs, 2008-2020 (Company Wide License)|1164|~1429~3348~~
Antibiotics and Drug Resistance 2008~
Published by BioPharm Reports, January 2008

This report reviews new drug innovation and strategy to combat antibiotic resistance mechanisms. This embraces current research-stage activities, patents published in the last five years, the entire pharmaceutical development pipeline and today's existing armoury of anti-bacterial drugs. The report reviews 370+ pipeline antibiotics and anti-bacterial technologies (from pre-clinical to Phase III/initial launch), 340+ antibiotic patents published between Jan 2002 and May 2007 and more than 200 fully launched antibiotics. It identifies and discusses new antibiotics, technologies and strategies at the anti-bacterial mechanistic level, that are specifically being developed to combat resistance mechanisms. The opportunities which they potentially offer in tackling the increasing global threat of antibiotic resistance, are discussed.~Published by BioPharm Reports, January 2008

This report reviews new drug innovation and strategy to combat antibiotic resistance mechanisms. This embraces current research-stage activities, patents published in the last five years, the entire pharmaceutical development pipeline and today's existing armoury of anti-bacterial drugs. The report reviews 370+ pipeline antibiotics and anti-bacterial technologies (from pre-clinical to Phase III/initial launch), 340+ antibiotic patents published between Jan 2002 and May 2007 and more than 200 fully launched antibiotics. It identifies and discusses new antibiotics, technologies and strategies at the anti-bacterial mechanistic level, that are specifically being developed to combat resistance mechanisms. The opportunities which they potentially offer in tackling the increasing global threat of antibiotic resistance, are discussed.

Overview

This report gives a comprehensive and detailed review of pipeline, emerging and current antibiotics and anti-bacterial technologies and their potential to provide more effective long-term therapies. More than 900 drugs, drug candidates and developmental compounds are identified, discussed and classified on the basis of their mode of action, developmental stage, activities and capabilities and by companies and research groups responsible for taking these activities forward. Moreover, they are considered in terms of their importance and potential to combat resistant pathogens, as part of the global effort to find alternatives to current antibiotics, which have lost or are losing their effectiveness against common and serious pathogens. The report looks in depth at current developments and thinking on how antibiotic resistance can be tackled technically and strategically, from improvements to existing drugs and drug combinations, to novel molecules, new and more promising drug targets and approaches to tackling resistance at its source. More detailed information on this report is given in the printable Report Description, which is linked to this page.

Combating Antibiotic Resistance

This review examines more than 370 pipeline candidates and 340 antibiotic patents, published between Jan 2002 and May 2007. These patents were selected from more than 1800 patents citing “anti-infectives”, published over the same period. Strategies being developed to combat resistance mechanisms include the identification of new selective targets, the selection of targets which may preclude genomic/phenotypic adaptation by bacteria, or where this is considered more difficult, combined activity molecules, molecules which inhibit stress-induced mutational emergence of resistance genes in response to synthetic antibiotics, novel antibacterial technologies, new targeting strategies and synthetic or semi-synthetic approaches vs. drugs of natural origin. Other areas reviewed include virulence targeting, the dissemination of adaptable traits, predicting resistance and the developing importance of pathogenomics.

Global Surveillance and Costs

This report gives detailed recently published figures on antibiotic resistance, from more than 35 countries. These data were obtained from the European Antimicrobial Resistance Surveillance System (EARSS) in Europe, by the Health Protection Agency in the UK, by the Active Bacterial Core surveillance (ABCs) Project in the US, by China's National Center for Antimicrobial Resistance and other sources. These data show increasing levels of antibiotic resistance globally and the report lists them by pathogen and antibiotic. Whilst definitive statistics are not available, there is a strong link between antibiotic resistant pathogens and levels of hospital-acquired infections. In the US it is reported that 50–60% of all hospital-acquired infections are caused by antibiotic resistant bacteria, whilst some experts suggest that the vast majority of nosocomial infections are due to resistant pathogens. The costs associated with these infections therefore provide an important measure of the failure of current antibiotics. According to the US Centers for Disease Control and Prevention (CDC, 2002), 1.7 million patients per year in the US acquire an infection whilst in hospital, resulting in 99,000 (5.8%) deaths. Recent figures from the US indicate that costs associated with these infections in the US at $6.7 billion and are around $1.7 billion in the UK. This report estimates that hospital-acquired infections in the developed world costs more than $32.5 billion, higher than current global sales on antibiotics. Others estimate that outpatient costs due to antibiotic resistance in the US lie between $400 million and $18.6 billion and inpatient costs several times higher. It is estimated in this report that hospital-acquired infection levels in the developed world could be higher than 7 million and deaths could exceed 400,000. Given the rapid rise of bacterial resistance in China, with a population of 1.3 billion (where resistance levels are reported to be growing faster than in any other country) and in Asia as a whole (total population 3.7 billion), these figures are likely to be significantly higher.

Questions Answered
  1. What strategies, drug molecules and technologies are being developed specifically to combat antibiotic resistance and where are they positioned in the development programme (from research, pre-clinical to Phase III/initial launch through to present day fully launched)
  2. Which technologies at the anti-bacterial mechanistic level offer the greatest hope of success
  3. Which companies and research groups are developing new drugs and technologies to fight antibiotic resistance
  4. What is the current full-listing of pipeline, patent (research) stage and fully launched anti-bacterials
  5. What are the current official global resistance antibiotic resistance levels and trends
  6. What are the costs of antibiotic resistance financially and in human terms, and how will this drive new drug development

Table of contents~Single User Licence|1081|Departmental Licence|1082|Company-Wide Licence|1083|~1429~3269~~
Erectile Dysfunction Market Assessment & Analysis 2007-2022~
Published by Visiongain, December 2007

The market for Erectile Dysfunction (ED) drugs is growing fast with a CAGR of 4.9% for the period 2006-2012. The ED market contains three leading drugs Viagra, Levitra and Cialis. Viagra, already a blockbuster drug, is the most popular and recognised brand on the market. Furthermore, high revenues are predicted by visiongain for the top three ED drugs, with Cialis reaching blockbuster status by 2007. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints. The purpose of this market analysis by visiongain is to examine prospects for Erectile Dysfunction (ED) drugs from 2007-2022, including sales forecasts for leading pharmaceutical products.~Published by Visiongain, December 2007

The market for Erectile Dysfunction (ED) drugs is growing fast with a CAGR of 4.9% for the period 2006-2012. The ED market contains three leading drugs Viagra, Levitra and Cialis. Viagra, already a blockbuster drug, is the most popular and recognised brand on the market.
Furthermore, high revenues are predicted by visiongain for the top three ED drugs, with Cialis reaching blockbuster status by 2007. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints. The purpose of this market analysis by visiongain is to examine prospects for Erectile Dysfunction (ED) drugs from 2007-2022, including sales forecasts for leading pharmaceutical products.

The market for Erectile Dysfunction (ED) drugs is growing fast with a CAGR of 4.9% for the period 2006-2012. The ED market contains three leading drugs Viagra, Levitra and Cialis. Viagra, already a blockbuster drug, is the most popular and recognised brand on the market.
Furthermore, high revenues are predicted by visiongain for the top three ED drugs, with Cialis reaching blockbuster status by 2007. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints. The purpose of this market analysis by visiongain is to examine prospects for Erectile Dysfunction (ED) drugs from 2007-2022, including sales forecasts for leading pharmaceutical products.

Most men experience ED at some points in their lives usually by the age of 40, but are not necessarily psychologically affected by it. Some men, however, experience chronic and complete ED. Over 150 million men worldwide are unable to achieve and maintain an erection adequate for satisfactory sexual intercourse; visiongain expects this figure to double by 2020. Despite its commonplace occurrence, ED is a notoriously under-reported, under-recognised, and an under-treated chronic illness.It is estimated that 85% to 90% of all ED goes undiagnosed.

The ED Market Report examines the market critically through a comprehensive review of available information. Sources include industrial databases, commercial news, published reports, economic research and consultation with experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

In particular, The ED Market concentrates on the following essential aspects of the market:

Why you should buy this report:

Why You Must Buy This Report:
This report features tables, graphs and charts, news, insights, the past and present developments in the ED Market. Amongst the catalogue of products in the ED pipeline is transdermal therapies. Neew innovative products for ED has generated a high level of interest from; top-tier companies, the major players in the ED circle and niche companies alike.

This visiongain report is the single tool to equip you with the latest trends in all regional markets and why drug companies are aiming for a new generation of drugs. Visiongain recommends this astute report to the major players in the field as it will arm you with the clinical challenges that larger companies face to date, thus the rising inherent cost of R&D expenditure to in order meet the requirements set by major regulatory authorities for larger evidence of clinical data before any authorisation.

The ED Market Assessment & Analysis 2007-2022 report is a must buy, because it presents in-depth and unbiased financial analysis for the near-term, medium-term and the long-term, market dynamics.

Unique benefits to you when you order this report:

Sample Page 1
Sample Page 2~Erectile Dysfunction Market Assessment & Analysis 2007-2022 (Single User License)|1147|Erectile Dysfunction Market Assessment & Analysis 2007-2022 (Departmental License)|1148|Erectile Dysfunction Market Assessment & Analysis 2007-2022 (Company Wide License)|1149|~1429~3338~~
The World Diabetes Market, 2006-2025~
Published by Visiongain, October 2007

Diabetes affects approximately 246 million people worldwide and this number is increasing. The IDF predict 380 million diabetics by 2025. The Global Diabetes drug treatment market was valued at over $21 billion in 2006 and the market is still expanding rapidly due to the high prevalence of diabetes and lifestyle changes. You cannot afford to ignore this market. To ignore this report when your competitors are reading it, would be a mistake. I urge you to read this report today.~Published by Visiongain, October 2007

Diabetes affects approximately 246 million people worldwide and this number is increasing. The IDF predict 380 million diabetics by 2025. The Global Diabetes drug treatment market was valued at over $21 billion in 2006 and the market is still expanding rapidly due to the high prevalence of diabetes and lifestyle changes. You cannot afford to ignore this market. To ignore this report when your competitors are reading it, would be a mistake. I urge you to read this report today.

Do you know what the prevalence of diabetes will be in 2007 to 2025? Will the oral anti-diabetics drugs and insulins still dominate the diabetes market until 2012? Which regions will be the main sales generator contributing sales into diabetes market? In addition, do you know what the drivers and restraints of the market are? This report explains just how this market will experience growth over the medium term future. This report not only reveals this, but also examines the key player’s strategies used to maximize profits and R&D as well as the relevant studies and trials. The new technologies for anti-diabetic treatment will be also illustrated in this report.

Analysis in the report looks at the 7 major markets, aswell as the leading 7 expanding markets:

7 Major markets:

E7 (expanding markets)

In the year 2000, the global retail sales of diabetes drugs was US$8.1 billion – the market has tripled in 6 years - Do you have as large a segment of that market as you want? What is the revenue for oral anti-diabetics compared to insulin – this report tells you.

In 2000 visiongain predicted that the retail market for diabetes medications would exceed US$20 billion annually by 2006 – we were right. If you want to know the shape and direction of the market in 2012 and 2025, you should order visiongain’s Diabetes Market report now.

This report is arranged to provide you with in-depth analysis of the diabetes drug market accompanied by forecasts by product type, country and application. Information on the leading diabetes drugs for the treatment of type 1 and 2 diabetes as well as a brief look at the drugs for treating the complications associated with diabetes will be presented in this report.

Forecasts of the market and an analysis of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category. The main areas of pharmaceutical developments within the diabetes market are delivery technologies for treatment of type 1 diabetes and drugs for the treatment of type 2 diabetes.

Market figures regarding the current value of the diabetes drug market is taken from the most recently available data of the global pharmaceutical industry.

Key Market for the Future

In this report the treatments of diabetes will be examined in terms of the classification of drugs, the current markets and sales forecasts for leading drugs as well as new block busters.

According to the findings of this new 164+ page report, visiongain reveals that oral anti-diabetic therapies are set to dominate the market over the forecast period (2007-2012); insulin therapies will also expand rapidly. Visiongain predicts that the diabetes market will continue to show significant growth for what is an already large market. New blockbusters: Januvia, Galvus, Byetta and Levemir will bring significant sales into diabetes market.

Actos and Lantus are existing leading products for oral anti-diabetic drugs and insulin. However, are there any others which can compete with this for market share or beat its dominance? This report answers that question with an analysis of other players in the market.

Why You Must Buy This Report?

This report features over 35 tables, 43 charts, news, insights, the latest developments and an in depth survey of the diabetes market with up-to-date analysis. This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company 'the edge' over your competitors. You can not afford to be without this latest report from visiongain.

With an increasingly aged population and unmet medical needs this market is set to grow rapidly, but by how much? This report will tell you. Brought together into one easy to read, easily digested format, this report will keep you fully informed and up-to-date on the global diabetes pharmaceutical market.

Key questions that this report answers are:

Put together with in-depth primary research and interviews, this report is not available anywhere else.

Sample Pages~The World Diabetes Market, 2006-2025 (single user license)|1114|The World Diabetes Market, 2006-2025 (departmental license)|1115|The World Diabetes Market, 2006-2025 (company wide license)|1116|~1429~3304~~
The Global Pain Pharmaceutical Market Analysis & Forecasts 2007-2022~
Published by Visiongain, September 2007

The global pain pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 4.56% to 2012. Visiongain's latest report, "The Global Pain Pharmaceutical Market 2007-2022 ", explains just how this market will experience growth over the medium term future. The report also highlights forecast for 2022, so that you and your company can make longer term plans. Don't let your competitors get the head-start on you, order this report today.~Published by Visiongain, September 2007

The global pain pharmaceutical market is set to become a serious growth area experiencing a compound annual growth rate of 4.56% to 2012. Visiongain's latest report, "The Global Pain Pharmaceutical Market 2007-2022 ", explains just how this market will experience growth over the medium term future. The report also highlights forecast for 2022, so that you and your company can make longer term plans. Don't let your competitors get the head-start on you, order this report today.

Key questions answered in this report

  1. Current and future key products that will drive the pain market
  2. The affects of patent expiry on key blockbuster drugs within the pain market
  3. How the withdrawal of COX-2 inhibitors impacted the pain market.
  4. The key companies involved in the industry, in terms of current and future aims and objectives
  5. How the safety of the narcotic drugs have affected the market
  6. The affects of reformulations of existing and new drugs on the market
The world market is currently valued at $31.1bn and revenues are forecasted to increase just under $40bn in 2012. But what will it be in 2022? This report tells you. Do you know what the drivers and restraints of the market are? This report not only reveals these, but also details what strategies can be used to maximize profits from the drivers and restraints in terms of a SWOT analysis. Ensure your organisation is successful in this market by reserving your copy of visiongain's report today.

According to the findings of the new 135+ page report, visiongain reveals that the non-narcotics market is set to dominate the pain market over the forecast period (2007-2012), accounting for almost 36.8% of market revenues by 2012. This market is set for growth right through the next 15 years and this report will help you plan. Reserve your copy today.

Find out who are the major companies involved in the pain market today and in the future. And what R&D opportunities exist for 'new-comers' to the pain pharmaceutical market. Analyse the pipeline of pain products and how it effects your future product launches and partners.

In the process of providing a thorough evaluation of the